Gamimune N could be a sterilized answer made of human plasma. It contains the antibodies to assist your bodyshield itself against infection from varied diseases.

Gamimune N is employed to treat primary immune deficiency conditions during which severe impairment of proteinforming capability has been shown. Gamimune N is additionally wont to increase platelets (blood activity cells) inindividuals with upset purpura hemorrhagica (ITP).

Gamimune N may additionally be used for functions unlisted during this medication guide.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Carimune, Flebogamma, Gammagard, Gammagard S/D, Gammaplex, Gammar-P I.V., Gamunex, Octagam, Polygam S/D, Privigen, Sandoglobulin
  • Get emergency medical help if you have any of these signs of an allergic reaction to Gamimune N: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as:

    urinating less than usual or not at all;
    drowsiness, confusion, mood changes, increased thirst, loss of appetite, nausea and vomiting;
    swelling, weight gain, feeling short of breath;
    wheezing, chest tightness;
    feeling like you might pass out;
    fever with headache, neck stiffness, chills, increased sensitivity to light, purple spots on the skin, and/or seizure (convulsions); or
    pale or yellowed skin, dark colored urine, fever, confusion or weakness.
    Less serious Gamimune N side effects may include:

    mild headache;
    dizziness;
    tired feeling;
    back pain, muscle cramps;
    minor chest pain; or
    flushing (warmth, redness, or tingly feeling).
  • Usual Adult Dose for Bone Marrow Transplantation 20 years or older: 400 to 500 mg/kg/dose IV, given as an infusion, every week for 3 months, then once a month Usual Adult Dose for Chronic Lymphocytic Leukemia 400 mg/kg/dose IV, given as an infusion, every 3 weeks Usual Adult Dose for Idiopathic (Immune) Thrombocytopenic Purpura Initial dose: 400 to 1000 mg/kg/day IV, given as an infusion, for 2 to 5 days Maintenance: 400 to 1000 mg/kg/dose IV, given as an infusion, every 3 to 6 weeks based on clinical response and platelet count Usual Adult Dose for Kawasaki Disease 2000 mg/kg IV, given as an infusion, over 10 to 12 hours The dose may need to be repeated if response is inadequate. Usual Adult Dose for Primary Immunodeficiency Syndrome 300 to 600 mg/kg/dose IV, given as an infusion, once every 3 to 4 weeks Usual Adult Dose for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Loading dose: 2 g/kg IV, given as an infusion, in divided doses over 2 to 4 consecutive days Maintenance dose: 1 g/kg IV, given as an infusion, over 1 day or 0.5 g/kg IV infusion on 2 consecutive days, every 3 weeks Usual Adult Dose for Polymyositis/Dermatomyositis Study (n=35) 1 g/kg/day IV, given as an infusion, for 2 consecutive days per month, for 4 to 6 months Usual Pediatric Dose for Chronic Lymphocytic Leukemia 400 mg/kg/dose IV, given as an infusion, every 3 to 4 weeks Usual Pediatric Dose for HIV Infection 400 mg/kg/dose every 2 to 4 weeks in those patients with hypogammaglobulinemia (IgG less than 400 mg/dL). Consider IGIV for HIV-infected children who have recurrent, serious bacterial infections during a 1 year period. Usual Pediatric Dose for Idiopathic (Immune) Thrombocytopenic Purpura Initial dose: 400 to 1000 mg/kg/day IV, given as an infusion, for 2 to 5 consecutive days (total dose: 2 g/kg) Maintenance: 400 to 1000 mg/kg/dose IV, given as an infusion, every 3 to 6 weeks based on clinical response and platelet count Usual Pediatric Dose for Kawasaki Disease 2000 mg/kg IV, given as a single dose, over 10 to 12 hours; should be used in combination with aspirin. If signs and symptoms persist greater than or equal to 36 hours after completion of the infusion, retreatment with a second 2000 mg/kg infusion should be considered. Usual Pediatric Dose for Primary Immunodeficiency Syndrome Primary immunodeficiency disorders: Adjust dose/frequency based on desired IgG concentration and clinical response. Manufacturers dosing recommendations vary based on individual product used. General dosing range: 200 to 800 mg/kg IV every 3 to 4 weeks; maintain a trough IgG concentration of 500 mg/dL. Usual Pediatric Dose for Chronic Inflammatory Demyelinating Polyradiculoneuropathy 400 mg/kg/day for 5 days once each month or 1 g/kg/day for 2 days once each month